



## **Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024**

March 6, 2024

WATERTOWN, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the Leerink Partners Global Biopharma Conference 2024 on Monday, March 11<sup>th</sup> at 10:40 am ET.

A live webcast of the fireside chat will be available through the investor relations section of the Company's website at [ir.discmedicine.com](http://ir.discmedicine.com) and an archived replay will be available after the event.

### **About Disc**

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit [www.discmedicine.com](http://www.discmedicine.com).

### **Media Contact**

Peg Rusconi  
Verge Scientific Communications  
[prusconi@vergescientific.com](mailto:prusconi@vergescientific.com)

### **Investor Relations Contact**

Christina Tartaglia  
Stern Investor Relations  
[christina.tartaglia@sternir.com](mailto:christina.tartaglia@sternir.com)